Evidence map›Paper›PMID 20580052›Full record

ArticleVirology2010

Palmitoylation of SARS-CoV S protein is necessary for partitioning into detergent-resistant membranes and cell-cell fusion but not interaction with M protein.

Corrin E McBride, Carolyn E Machamer

2 registry-linked trialsAbstract read
In one paragraph

Article in Virology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 69 papers.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04517396 phase2completednot on this mapstarted 2020, after this paper: background citation

FEnofibRate as a Metabolic INtervention for Coronavirus Disease 2019

TypeinterventionalSponsorUniversity of PennsylvaniaRan2020 to 2022Enrolled701ConditionsCovid19ArmsFenofibrate/fenofibric acid, Placebo, Usual care
NCT04661930 phase3unknown statusnot on this mapstarted 2021, after this paper: background citation

A Study of a 10-days Fenofibrate Treatment, or Until Discharge From Hospital, Among COVID-19 Infected Patients Requiring Hospitalization

TypeinterventionalSponsorYaakov NahmiasRan2021 to 2022Enrolled55ConditionsCorona Virus Disease (COVID-19), Respiratory Distress Syndrome, SARS-CoV-2 InfectionArmsTriCor® 145mg tablets, Placebo, Usual care
3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 100 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Perturbation ofJournal of virology · 2025
    Article
  12. Review
  13. Article
  14. State-of-the-Art Molecular Biophysics in Russia.International journal of molecular sciences · 2024
    Article
  15. Article
  16. Article
  17. Article
  18. Inconspicuous Yet Indispensable: The Coronavirus Spike Transmembrane Domain.International journal of molecular sciences · 2023
    Review
  19. Article
  20. Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Corrin E McBrideDepartment of Cell Biology, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Carolyn E Machamer
Johns Hopkins University · US

Funding

BIOCHEMISTRY, CELLULAR AND MOLECULAR BIOLOGY PROGRAMT32GM007445 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI GREEN, RACHEL · 1985 to 2021
$24.1M
Assembly and release of the SARS coronavirusR21AI072312 · NIAID · JOHNS HOPKINS UNIVERSITY · PI MACHAMER, CAROLYN E · 2007 to 2008
$447k
NIAID NIH HHS R21 AI072312NIGMS NIH HHS T32 GM007445PHS HHS R21 A1072312
6 · The paper itself

Abstract

Coronaviruses are enveloped RNA viruses that generally cause mild disease in humans. However, the recently emerged coronavirus that caused severe acute respiratory syndrome (SARS-CoV) is the most pathogenic human coronavirus discovered to date. The SARS-CoV spike (S) protein mediates virus entry by binding cellular receptors and inducing fusion between the viral envelope and the host cell membrane. Coronavirus S proteins are palmitoylated, which may affect function. Here, we created a non-palmitoylated SARS-CoV S protein by mutating all nine cytoplasmic cysteine residues. Palmitoylation of SARS-CoV S was required for partitioning into detergent-resistant membranes and for cell-cell fusion. Surprisingly, however, palmitoylation of S was not required for interaction with SARS-CoV M protein. This contrasts with the requirement for palmitoylation of mouse hepatitis virus S protein for interaction with M protein and may point to important differences in assembly and infectivity of these two coronaviruses.

Indexed as

AnimalsCell FusionCell MembraneChlorocebus aethiopsCoronavirus M ProteinsDetergentsGene Expression Regulation, ViralHumansLipoylationMembrane GlycoproteinsMiceSevere acute respiratory syndrome-related coronavirusSpike Glycoprotein, CoronavirusVero CellsViral Envelope ProteinsViral Matrix ProteinsCoronavirus M ProteinsDetergentsMembrane GlycoproteinsM protein, SARS-CoVSpike Glycoprotein, Coronavirusspike glycoprotein, SARS-CoVspike protein, mouse hepatitis virusViral Envelope ProteinsViral Matrix Proteins

Identifiers

PMID20580052
PMCPMC2914208
OpenAlexW1971894038

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.